{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:16:21Z","timestamp":1791807381017,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["neuromodulationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromodulation: Technology at the Neural Interface"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1111\/ner.12474","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T07:49:18Z","timestamp":1470383358000},"page":"689-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson\u2019s Disease in the United States"],"prefix":"10.1016","volume":"19","author":[{"given":"Jan B.","family":"Pietzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail M.","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Marks, Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ner.12474_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.parkreldis.2012.07.004","article-title":"Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson\u2019s disease: concept and standards of the EARLYSTIM-study","volume":"19","author":"Deuschl","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ner.12474_bib2","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1136\/jnnp.2005.063206","article-title":"Stimulation of the subthalamic nucleus in Parkinson\u2019s disease: a 5 year follow up","volume":"76","author":"Schupbach","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ner.12474_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","article-title":"A randomized trial of deep-brain stimulation for Parkinson\u2019s disease","volume":"355","author":"Deuschl","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/ner.12474_bib4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","article-title":"Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease","volume":"362","author":"Follett","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ner.12474_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2008.929","article-title":"Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial","volume":"301","author":"Weaver","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/ner.12474_bib6","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.25164","article-title":"Parkinson\u2019s disease medication use and costs following deep brain stimulation","volume":"27","author":"Weaver","year":"2012","journal-title":"Mov Disord"},{"key":"10.1111\/ner.12474_bib7","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.23903","article-title":"Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson\u2019s disease","volume":"26","author":"Zibetti","year":"2011","journal-title":"Mov Disord"},{"key":"10.1111\/ner.12474_bib8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.parkreldis.2014.01.012","article-title":"Long-term outcome of subthalamic nucleus DBS in Parkinson\u2019s disease: from the advanced phase towards the late stage of the disease?","volume":"20","author":"Rizzone","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1111\/ner.12474_bib9","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ner.12474_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00415-013-7148-z","article-title":"The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson\u2019s disease","volume":"261","author":"Eggington","year":"2014","journal-title":"J Neurol"},{"key":"10.1111\/ner.12474_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.25407","article-title":"Cost-effectiveness of deep brain stimulation in patients with Parkinson\u2019s disease","volume":"28","author":"Dams","year":"2013","journal-title":"Mov Disord"},{"key":"10.1111\/ner.12474_bib12","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/mds.21652","article-title":"Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson\u2019s disease","volume":"22","author":"Valldeoriola","year":"2007","journal-title":"Mov Disord"},{"key":"10.1111\/ner.12474_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.57.4.663","article-title":"Deep brain stimulation in the treatment of Parkinson\u2019s disease: a cost-effectiveness analysis","volume":"57","author":"Tomaszewski","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/ner.12474_bib14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/ner.12474_bib15","series-title":"Cost-effectiveness in health and medicine","author":"Gold","year":"1996"},{"key":"10.1111\/ner.12474_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times","volume":"25","author":"Zhao","year":"2010","journal-title":"Mov Disord"},{"key":"10.1111\/ner.12474_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200220090-00005","article-title":"Cost effectiveness of treatment of Parkinson\u2019s disease with entacapone in the United States","volume":"20","author":"Palmer","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/ner.12474_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1212\/WNL.0b013e31825dcdc1","article-title":"Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes","volume":"79","author":"Weaver","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ner.12474_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00415-002-0711-7","article-title":"Evaluation of healthcare utilization and health status of patients with Parkinson\u2019s disease treated with deep brain stimulation of the subthalamic nucleus","volume":"249","author":"Spottke","year":"2002","journal-title":"J Neurol"},{"key":"10.1111\/ner.12474_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1111\/ner.12474_bib21","first-page":"S87","article-title":"Parkinson\u2019s disease: health-related quality of life, economic cost, and implications of early treatment","volume":"16","author":"Chen","year":"2010","journal-title":"Am J Managed Care."},{"key":"10.1111\/ner.12474_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/practneurol-2012-000463","article-title":"When the going gets tough: how to select patients with Parkinson\u2019s disease for advanced therapies","volume":"13","author":"Worth","year":"2013","journal-title":"Pract Neurol"},{"key":"10.1111\/ner.12474_bib23","doi-asserted-by":"crossref","unstructured":"McIntosh E, Gray A, Daniels J et al. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson\u2019s: economic evaluation alongside the PD SURG trial. Mov Disord 2016; e-pub ahead of print. doi: 10.1002\/mds.26423.","DOI":"10.1002\/mds.26423"},{"key":"10.1111\/ner.12474_bib24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s disease with early motor complications","volume":"368","author":"Schuepbach","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/ner.12474_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/geront\/gnr151","article-title":"How are the costs of care for medical falls distributed? the costs of medical falls by component of cost, timing, and injury severity","volume":"52","author":"Bohl","year":"2012","journal-title":"Gerontologist"},{"key":"10.1111\/ner.12474_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1023\/A:1008903126315","article-title":"Patient preferences and utilities for \u2018off-time\u2019 outcomes in the treatment of Parkinson\u2019s disease","volume":"9","author":"Palmer","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1111\/ner.12474_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1532-5415.2010.02816.x","article-title":"A longitudinal analysis of total 3-year healthcare costs for older adults who experience a fall requiring medical care","volume":"58","author":"Bohl","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/ner.12474_bib28","unstructured":"Labor_USDo. http:\/\/www.bls.gov\/data\/inflation_calculator.htm. Accessed 12 18 2013."},{"key":"10.1111\/ner.12474_bib29","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1093\/brain\/awq221","article-title":"Motor and cognitive outcome in patients with Parkinson\u2019s disease 8 years after subthalamic implants","volume":"133","author":"Fasano","year":"2010","journal-title":"Brain"},{"key":"10.1111\/ner.12474_bib30","unstructured":"Arias E. United States Life Tables. 2008. National Vital Statistics Reports; Vol. 61, No. 3. Hyattsville, MD: National Center for Health Statistics; 2012."},{"key":"10.1111\/ner.12474_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3111\/13696998.2011.598201","article-title":"A cost-effectiveness analysis of levodopa\/carbidopa intestinal gel compared to standard care in late stage Parkinson\u2019s disease in the UK","volume":"14","author":"Lowin","year":"2011","journal-title":"J Med Econ"},{"key":"10.1111\/ner.12474_bib32","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A","article-title":"How does Parkinson\u2019s disease affect quality of life? a comparison with quality of life in the general population","volume":"15","author":"Schrag","year":"2000","journal-title":"Mov Disord"}],"container-title":["Neuromodulation: Technology at the Neural Interface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fner.12474","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109471592106030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109471592106030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ner.12474\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:53:00Z","timestamp":1761083580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109471592106030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S109471592106030X"],"URL":"https:\/\/doi.org\/10.1111\/ner.12474","relation":{},"ISSN":["1094-7159"],"issn-type":[{"value":"1094-7159","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson\u2019s Disease in the United States","name":"articletitle","label":"Article Title"},{"value":"Neuromodulation: Technology at the Neural Interface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ner.12474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}